Evaluation of serum levels during prolonged combination therapy with phenytoin and phenobarbitone. 1977

F O Müller, and A K Aucamp, and H K Hundt, and J M Steyn, and L R Olivier, and W H Wessels

When phenobarbitone was added to the treatment regimen of epileptic patients who received phenytoin only, the serum levels of phenytoin increased significantly within 6 weeks. Eleven weeks after the introduction of phenobarbitone, phenytoin levels had returned to those existing before phenobarbitone therapy. In view of possible complex pharmacokinetic interactions which might occur when phenobarbitone is added to a regimen of phenytoin, or vice versa, frequent measurement of serum drug levels appears to be indicated for up to 10 weeks after effecting a change in treatment. During this period a constant change in serum levels could be expected, resulting either in toxicity or lack of efficacy.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010634 Phenobarbital A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. Phenemal,Phenobarbitone,Phenylbarbital,Gardenal,Hysteps,Luminal,Phenobarbital Sodium,Phenobarbital, Monosodium Salt,Phenylethylbarbituric Acid,Acid, Phenylethylbarbituric,Monosodium Salt Phenobarbital,Sodium, Phenobarbital
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

F O Müller, and A K Aucamp, and H K Hundt, and J M Steyn, and L R Olivier, and W H Wessels
November 1974, The British journal of psychiatry : the journal of mental science,
F O Müller, and A K Aucamp, and H K Hundt, and J M Steyn, and L R Olivier, and W H Wessels
January 1977, Scandinavian journal of social medicine,
F O Müller, and A K Aucamp, and H K Hundt, and J M Steyn, and L R Olivier, and W H Wessels
March 1979, Obstetrics and gynecology,
F O Müller, and A K Aucamp, and H K Hundt, and J M Steyn, and L R Olivier, and W H Wessels
August 1976, Acta neurologica Scandinavica,
F O Müller, and A K Aucamp, and H K Hundt, and J M Steyn, and L R Olivier, and W H Wessels
January 1976, Lancet (London, England),
F O Müller, and A K Aucamp, and H K Hundt, and J M Steyn, and L R Olivier, and W H Wessels
September 1977, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
F O Müller, and A K Aucamp, and H K Hundt, and J M Steyn, and L R Olivier, and W H Wessels
December 1978, Scandinavian journal of clinical and laboratory investigation,
F O Müller, and A K Aucamp, and H K Hundt, and J M Steyn, and L R Olivier, and W H Wessels
April 1982, British journal of clinical pharmacology,
F O Müller, and A K Aucamp, and H K Hundt, and J M Steyn, and L R Olivier, and W H Wessels
July 1957, The Journal of mental science,
F O Müller, and A K Aucamp, and H K Hundt, and J M Steyn, and L R Olivier, and W H Wessels
January 1986, Indian journal of physiology and pharmacology,
Copied contents to your clipboard!